Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation‐related signalling pathways
British Journal of Pharmacology2019Vol. 176(24), pp. 4745–4759
Citations Over TimeTop 10% of 2019 papers
Xing Zhang, Hong Lu, Shuangshuang Xie, Cunzao Wu, Yangyang Guo, Yanyi Xiao, Shizhang Zheng, Hengyue Zhu, Yan Zhang, Yongheng Bai
Abstract
Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in vivo and in vitro via proliferation-related pathways, making it a potential therapeutic agent for preventing renal fibrosis.
Related Papers
- → Resveratrol and derivatives for the prevention and treatment of cancer(2010)246 cited
- → Resveratrol cytotoxicity is energy‐dependent(2019)23 cited
- Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells(2009)
- → Resveratrol—The “Chateau Hormone” for Cardio Diabetic Protection(2014)1 cited
- → Resveratrol: Biochemistry and Functions(2009)2 cited